CMS is entering a new phase of federal drug pricing reform, moving the Most Favored Nation (MFN) concept from policy signaling into direct implementation. For Medicare Part D stakeholders, the GUARD model represents the most consequential application to date, reshaping rebate mechanics, manufacturer accountability, and long‑term program economics.
MFN: The Policy Framework Driving Change
The MFN initiative originated with a May 2025 executive order directing federal agencies to align U.S. drug prices with those paid in comparable high‑income countries. By early 2026, most targeted manufacturers had entered MFN‑related agreements, establishing international reference pricing as a credible federal tool.
Rather than applying a single price ceiling, MFN allows CMS to tailor benchmarks by program and drug class. This approach creates flexibility while increasing leverage over high‑cost, single‑source drugs.
GUARD: A Structural Shift for Medicare Part D
The GUARD model is a mandatory, five‑year Medicare Part D program (2027–2031) designed to increase manufacturer rebates and reduce beneficiary out‑of‑pocket costs.
Key features include:
- Application to single‑source Part D drugs exceeding 69 million dollars in annual spend (2027 threshold) that are not under Part D Drug Price Negotiation.
- Inclusion of protected classes, preserving statutory access requirements.
- Use of international price benchmarks to calculate manufacturer rebate obligations.
- Operation in regions covering 25 percent of Part D beneficiaries, including PDP and MA‑PD enrollment.
- Redirection of rebates to the Medicare Supplementary Medical Insurance Trust Fund rather than to plans.
For Part D sponsors, GUARD represents a fundamental change. Rebates become a federal mechanism rather than a plan‑level lever, which may alter formulary strategy, contracting approaches, and competitive positioning across markets.
Where GENEROUS and GLOBE Fit In
While GENEROUS (Medicaid) and GLOBE (Medicare Part B) do not directly affect Part D operations, they reinforce the same direction of travel: increased use of international benchmarks, mandatory rebate obligations, and targeted selection of high‑cost drugs. Together, these models signal a broader CMS strategy that will likely influence future Part D policy and design considerations.
BluePeak can help!
As MFN pricing and the GUARD model reshape Medicare Part D, our Medicare consulting team helps plans and industry partners understand policy requirements, assess financial exposure, and prepare for operational change. We support organizations with targeted regulatory interpretation, GUARD impact modeling, formulary and contracting strategy alignment, and implementation readiness. Our focus is helping Part D stakeholders anticipate change, reduce uncertainty, and make informed decisions as CMS pricing reforms move into execution.
